TCL Archive FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint. July 21, 2006
TCL Archive Phase III Trial of Avastin and Temozolomide Shows Reduced Risk of Cancer Progression November 30, 2012